Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2024-10-29
- Target Recruit Count
- 60
- Registration Number
- NCT06040346
- Locations
- 🇰🇪
Kisumu County Referral Hospital, Kisumu, Kenya
To Evaluate the Safety and Efficacy of Meplazumab in Treatment of Post-COVID-19
Phase 3
Completed
- Conditions
- Post-COVID-19
- Interventions
- Biological: Meplazumab for injectionOther: Normal saline
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-28
- Target Recruit Count
- 121
- Registration Number
- NCT05813587
- Locations
- 🇨🇳
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
Study on the Safety and Efficacy of Meplazumab for Injection in Severe Patients With COVID-19
Phase 3
Completed
- Conditions
- COVID-19
- Interventions
- Biological: Meplazumab for injectionOther: Normal saline
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2024-05-28
- Target Recruit Count
- 108
- Registration Number
- NCT05679479
- Locations
- 🇨🇳
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
Phase 3
Withdrawn
- Conditions
- COVID-19
- Interventions
- Biological: Meplazumab foe injectionOther: Normal saline
- Locations
- 🇨🇳
First Affiliated Hospital of the Air Force Medical University, Xi'an, China
the Safety and Efficacy of Meplazumab in Patients With COVID-19
Phase 2
Completed
- Conditions
- Covid19
- Interventions
- Drug: Sterile normal saline (0.9%)
- First Posted Date
- 2021-11-09
- Last Posted Date
- 2023-09-15
- Target Recruit Count
- 150
- Registration Number
- NCT05113784
- Locations
- 🇨🇳
The Third People's Hospital Of Shenzhen, Shenzhen, China
🇨🇳Shanghai Public Health Clinical Center, Shanghai, Shanghai, China
Study to Assess the Effect of Meplazumab on COVID-19
Phase 2
Completed
- Conditions
- COVID-19
- Interventions
- Drug: Sterile normal saline (0.9%)
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2023-09-15
- Target Recruit Count
- 174
- Registration Number
- NCT04586153
- Locations
- 🇧🇷
Pesquisare Saúde, Santo André, Sao Paulo, Brazil
Clinical Study of Meplazumab to Treat With Malaria
Phase 1
Withdrawn
- Conditions
- Malaria (Plasmodium Falciparum)
- Interventions
- Drug: Sterile normal saline (0.9%)
© Copyright 2025. All Rights Reserved by MedPath